FDA Approves Ultragenyx Gene Therapy
Source Summary
The FDA has approved a gene therapy from Ultragenyx for an ultra-rare disease. The approval represents a validating win for mRNA research, according to biotech news coverage.
The FDA has approved a gene therapy from Ultragenyx for an ultra-rare disease. The approval represents a validating win for mRNA research, according to biotech news coverage.
No published comments yet.
The chart totals every SEC-reported transaction by month and share count, separating informative purchases and sales from non-informative awards, vesting, exercises, tax withholding and transfers. Records without a reported price remain included. Only informative purchases and sales affect the conservative sentiment signal.
Recent SEC-reported share and derivative transactions in Ultragenyx Pharmaceutical Inc..
0 discretionary purchases · 2 discretionary sales
Confidence: Medium
| Insiders | Activity | Description | Shares | Avg. price / share | Est. value | Trade date |
|---|---|---|---|---|---|---|
| Chief Financial OfficerHorn Howard | Informative sell | Common StockOpen-market or private transaction (S) | 7,066 | $15.27 | $107,898 | Oct 15, 2026 |
| SVP, Chief Accounting OfficerHuizenga Theodore Alan | Non-informative sell | Common StockReported 10b5-1 plan (S) | 1,283 | $13.57 | $17,410 | Sep 15, 2026 |
| SVP, Chief Accounting OfficerHuizenga Theodore Alan | Informative sell | Common StockOpen-market or private transaction (S) | 161 | $13.99 | $2,252 | Sep 3, 2026 |
| EVP and Chief Legal OfficerParschauer Karah Herdman | Non-informative sell | Common StockReported 10b5-1 plan (S) | 1,900 | $24.92 | $47,348 | Aug 3, 2026 |
| Chief Financial OfficerHorn Howard | Non-informative sell | Common StockReported 10b5-1 plan (S) | 4,696 | $24.92 | $117,024 | Aug 3, 2026 |
As filed with the SEC. Estimated value is shown only for purchases or sales with a positive reported transaction price; awards, gifts and similar activity are not assigned an assumed market value. Amendments may change the record. This is not investment advice.
Quarterly reported positions. These filings can arrive up to 45 days after quarter-end and are not real-time trades.
Institutional ownership: 119.52%
Open short positions reported twice monthly; this is not daily short-sale volume.
Recent reported earnings per share compared with the analyst consensus available from Nasdaq.
| Owner | Activity | Change | Shares held | Value (thousands) | Reported |
|---|---|---|---|---|---|
| Blackrock, Inc. | Buy | 3,354,678 (45.957%) | 10,654,276 | $169,936 | 6/30/2026 |
| Vanguard Group Inc | Buy | 131,087 (1.294%) | 10,263,815 | $163,708 | 12/31/2025 |
| Rtw Investments, Lp | Buy | 4,148,100 (113.684%) | 7,796,895 | $124,360 | 6/30/2026 |
| Vanguard Portfolio Management Llc | Buy | 1,404,143 (26.07%) | 6,790,135 | $108,303 | 6/30/2026 |
| Aqr Capital Management Llc | Buy | 1,982,785 (43.311%) | 6,560,809 | $104,645 | 6/30/2026 |
| State Street Corp | Buy | 1,137,325 (22.649%) | 6,158,766 | $98,232 | 6/30/2026 |
| Vanguard Capital Management Llc | Buy | 106,660 (2.546%) | 4,296,491 | $68,529 | 6/30/2026 |
| Two Sigma Investments, Lp | Buy | 1,415,380 (64.166%) | 3,621,200 | $57,758 | 6/30/2026 |
| Sands Capital Management, Llc | Sell | -56,165 (-1.747%) | 3,158,368 | $50,376 | 6/30/2026 |
| Jacobs Levy Equity Management, Inc | Buy | 1,508,648 (105.421%) | 2,939,719 | $46,889 | 6/30/2026 |
| Frontier Capital Management Co Llc | Buy | 656,754 (29.973%) | 2,847,936 | $45,425 | 6/30/2026 |
| Geode Capital Management, Llc | Buy | 729,437 (39.442%) | 2,578,828 | $41,132 | 6/30/2026 |
Source: Nasdaq
| Settlement date | Short interest | Avg. daily volume | Change vs. previous report | Days to cover |
|---|---|---|---|---|
| Sep 30, 2026 | 20,349,877 | 6,502,013 | +22.80% | 3.13 |
| Sep 15, 2026 | 16,571,956 | 7,461,648 | -3.34% | 2.22 |
| Aug 31, 2026 | 17,144,354 | 2,143,209 | +7.91% | 8.00 |
| Aug 14, 2026 | 15,887,767 | 2,042,547 | +6.18% | 7.78 |
| Jul 31, 2026 | 14,963,396 | 1,807,137 | +11.38% | 8.28 |
| Jul 15, 2026 | 13,435,087 | 1,937,159 | -17.16% | 6.94 |
| Jun 30, 2026 | 16,217,153 | 4,501,008 | +13.31% | 3.60 |
| Jun 15, 2026 | 14,312,759 | 1,617,040 | — | 8.85 |
Source: Nasdaq
| Fiscal quarter | Reported | EPS | Consensus | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | -0.90 | -1.27 | +29.13% |
| Mar 2026 | May 5, 2026 | -1.84 | -1.55 | -18.71% |
| Dec 2025 | Feb 12, 2026 | -1.29 | -1.2 | -7.5% |
| Sep 2025 | Nov 4, 2025 | -1.81 | -1.23 | -47.15% |
Source: Nasdaq
